BioCentury
ARTICLE | Emerging Company Profile

Calydon: Lysing prostate cancer

November 23, 1998 8:00 AM UTC

Calydon wants to cure prostate cancer and is pursuing an approach that moves past traditional gene therapies, which encode for a therapeutic gene, to using regulatory genes to create cytolytic (cell lysing) viruses.

The company's core technology, Attenuated Replication-Competent Adenovirus (ARCA), was developed to incorporate the discovery of PSE (prostate tissue-specific enhancer), a gene that regulates the growth of prostate tissue...